BBIO News and Press, BridgeBio Pharma Inc. From 02/24/26

2026-02-24 16:06:33 ET More on BridgeBio Pharma BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia Transcript BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in...

$154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectively BridgeBio reported three positive Phase 3 trial readouts in just over three months, a demonstration...

Interface Inc. (TILE) is expected to report $0.4 for Q4 2025 Evolent Health Inc Class A (EVH) is expected to report $-0.03 for Q4 2025 MercadoLibre Inc. (MELI) is expected to report $11.77 for Q4 2025 Clean Energy Fuels Corp. (CLNE) is expected to report $-0.1 for Q4 2025 Kiniksa ...

2026-02-23 19:20:00 ET The following segment was excerpted from the Allspring Premier Large Company Growth Fund Q4 2025 Commentary. ... Read the full article on Seeking Alpha For further details see: Allspring Premier Large Company Growth...

2026-02-23 14:34:32 ET More on CRISPR Therapeutics, Intellia Therapeutics Crispr Therapeutics: Very High Risk, But Even Higher Potential Reward CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript Crispr: Emphasis Shifts...

PALO ALTO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will parti...

PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its fourth quarter and fu...

2026-02-12 21:15:00 ET The following segment was excerpted from the Allspring Growth Fund Q4 2025 Commentary. ... Read the full article on Seeking Alpha For further details see: Allspring Growth Fund Q4 2025 Fund Performers And Detractors

2026-02-12 17:54:19 ET BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia February 12, 2026 8:00 AM EST... Read the full article on Seeking Alpha For further details see: BridgeBio Pharma, Inc. (BBIO) Di...

2026-02-12 15:04:10 ET Andrew Tsai from Jefferies issued a price target of $100.00 for BBIO on 2026-02-12 19:07:50. The adjusted price target was set to $100.00. At the time of the announcement, BBIO was trading at $76.06. The overall price target consensus is at $96.82 ...